Publications by authors named "Juliane Hey"
Article Synopsis
- The study assessed the performance of the Access anti-HBc Total assay on the DxI 9000 system, involving samples from blood donors and patients to evaluate diagnostic accuracy.
- The assay showed a clinical specificity of 99.58% for blood donors and 99.27% for hospitalized patients, meaning it accurately identified negatives in nearly all cases.
- Additionally, the Access assay demonstrated high sensitivity at 99.78% for positive samples and detected seroconversion earlier than a comparator assay by approximately 1.4 days.
Introduction: This study evaluated the clinical and analytical performances of the Access HBsAg and the Access HBsAg Confirmatory assays on the DxI 9000 Access Immunoassay Analyzer (Beckman Coulter, Inc.).
Materials And Methods: Diagnostic specificity and sensitivity of the Access HBsAg and Access HBsAg Confirmatory assays were evaluated by comparing the Access assays to the final HBsAg sample status determined using the Architect, PRISM, or Elecsys HBsAg assays, along with Architect or PRISM HBsAg Confirmatory assays.
Although effective for bacterial lower respiratory tract infections (LRTIs), antibiotic treatment is often incorrectly prescribed for non-bacterial LRTIs. Procalcitonin has emerged as a promising biomarker to diagnose bacterial infections and guide antibiotic treatment decisions. As part of a regulatory submission to the U.
View Article and Find Full Text PDFObjective: Sepsis is a leading cause of mortality in noncoronary ICUs. Although immediate start of antibiotics reduces sepsis-related mortality, antibiotics are often administered for too long, leading to suboptimal treatment and, importantly, contributes to antimicrobial resistance. Prior literature suggests that procalcitonin correlates with infection and thus may help to guide the decision on when to stop antibiotic treatment.
View Article and Find Full Text PDF